D-0545-2026 Class II Ongoing

Recalled by Zydus Pharmaceuticals (USA) Inc — Pennington, NJ

FDA drug recall D-0545-2026 was initiated by Zydus Pharmaceuticals (USA) Inc on Apr 29, 2026 and is designated Class II. Reason for recall: CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit The recall status is ongoing. Affected quantity: 10,992 bottles.

Recall details

Product Type
Drugs
Report Date
May 27, 2026
Initiation Date
Apr 29, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
10,992 bottles

Product description

Erythromycin Tablets, USP, 500 mg, 30 tablets per bottle, Rx only, Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534; (NDC 70710-1048-3).

Reason for recall

CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Distribution pattern

Nationwide within the U.S

Code information

Lots: a) M411147, Expires: 08/2026; M502100, M502099, Expires: 01/2027.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0545-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0545-2026. Report a data issue: hello@regdatalab.com.